1 October 2018 - NHS England has agreed to provide funding for Janssen’s Symtuza, a once-daily darunavir-based single tablet regimen (STR) for the treatment of HIV in adults and adolescents.

This decision allows clinicians across England to routinely prescribe Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) on the NHS for eligible patients.

Symtuza was approved for use in Europe back in September 2017, on the back of a Phase III programme showing that the STR’s safety and efficacy is equivalent to combined administration of the separate agents.

Read Pharma Times article